MESENCHYMAL STEM CELL THERAPY PROMOTES TEAR FILM STABILITY AND REDUCES OCULAR SURFACE INFLAMMATION IN KERATOCONJUNCTIVITIS SICCA IN SMALL ANIMALS
RSV · 25.06.2026 · 8 (06) · 1-27
DOI: 10.66104/6mbt6042 ↗Kurz gefasst
Fachartikel in der Zeitschrift RSV, online erschienen am 25.06.2026. Verfasst von Enrico Jardim Clemente Santos und 2 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Keratoconjunctivitis sicca (KCS), or "dry eye," is an ophthalmic condition prevalent in dogs and, to a lesser extent, in cats, characterized by deficient production of the aqueous component of the tear film. Its etiology is predominantly immune-mediated, resulting in chronic inflammation and degeneration of the lacrimal glands. Although conventional treatment with topical immunomodulators is effective, many patients are resistant or require lifelong administration, compromising adherence and animal welfare. Recently, mesenchymal stem cell (MSCs) therapy has emerged as a promising alternative due to its immunomodulatory, anti-inflammatory, and regenerative properties. The objective of this study is to synthesize the evidence on the use of MSCs in the treatment of KCS in small animals. Clinical studies demonstrate that the application of MSCs, mainly derived from adipose tissue (AD-MSCs) and administered periglandularly or topically, promotes a statistically significant increase in tear production, as measured by the Schirmer Tear Test (STT). In addition to quantitative improvement, there was a significant reduction in corneal opacity, vascularization, and mucopurulent secretion. The therapy proved to be safe, with no serious adverse effects, and with prolonged benefits even after a single intervention in refractory cases. It is concluded that MSCs transplantation represents a viable and effective therapeutic advance for KCS in dogs and cats, offering potential restoration of ocular surface homeostasis and overcoming the limitations of traditional pharmacological protocols. However, standardization of culture and application protocols is still necessary for the definitive clinical consolidation of the technique in the current veterinary scenario, aiming to optimize long-term results.
Zitieren
APA
Santos, E. J. C., Mazzeo, A., & Braga, C. L. (2026). MESENCHYMAL STEM CELL THERAPY PROMOTES TEAR FILM STABILITY AND REDUCES OCULAR SURFACE INFLAMMATION IN KERATOCONJUNCTIVITIS SICCA IN SMALL ANIMALS. RSV, 8(06), 1-27. https://doi.org/10.66104/6mbt6042
Vancouver
Santos EJC, Mazzeo A, Braga CL. MESENCHYMAL STEM CELL THERAPY PROMOTES TEAR FILM STABILITY AND REDUCES OCULAR SURFACE INFLAMMATION IN KERATOCONJUNCTIVITIS SICCA IN SMALL ANIMALS. RSV. 2026;8(06):1-27. doi:10.66104/6mbt6042
BibTeX
@article{Santos2026,
author = {Santos, Enrico Jardim Clemente and Mazzeo, Angela and Braga, Camila Landim},
title = {MESENCHYMAL STEM CELL THERAPY PROMOTES TEAR FILM STABILITY AND REDUCES OCULAR SURFACE INFLAMMATION IN KERATOCONJUNCTIVITIS SICCA IN SMALL ANIMALS},
journal = {RSV},
year = {2026},
volume = {8},
number = {06},
pages = {1--27},
doi = {10.66104/6mbt6042}
}
EUVIMED